1型单纯疱疹病毒突变体治疗肿瘤的研究进展  

Progess on Research of Herpes Simplex Virus Type 1 Mutants for Cancer Therapy

作　　者：龙亚红[1] 米彦霞[1] 李云春[1] 

机构地区：[1]四川大学华西医院核医学科,成都610041

出　　处：《生物医学工程学杂志》2008年第6期1446-1449,共4页Journal of Biomedical Engineering

基　　金：国家自然科学基金资助项目(30770604)

摘　　要：病毒溶瘤治疗的研究由来已久,但治疗多种人类恶性肿瘤的溶瘤病毒的选择构建仍在不断的探索与研究中。目前1型单纯疱疹病毒(HSV-1)被认为是最为有效的溶瘤病毒。作者阐述了溶瘤病毒治疗肿瘤的现状及研究机制、HSV-1的生物学特点、HSV-1突变体构建及其治疗肿瘤的现状,并探讨了放射性核素标记HSV-1突变体的可行性及标记物治疗肿瘤的前瞻性。For a long time past viruses have been recognized as being tumoricidal. At present, researchers are still pursuing studies and constructing more suitable oncolytic viruses for treating different malignant tumors. Herpes simplex virus type 1 （HSV-1） has been known as the most potential oncolytic virus among all the viruses. In this overview, we summarize the current situation of oncolytic viruses, the biology of HSV-1, its construction and application of its recombinant, and we debate on the feasibility and prospect of HSV-1 mutants labeled with radionuclides for cancer therapy.

关 键 词：溶瘤病毒 1型单纯疱疹病毒 突变体 放射性核素 肿瘤治疗 

分 类 号：R730.5[医药卫生—肿瘤]